Progress in the Treatment of Metastatic Melanoma

Published Online: Wednesday, September 26, 2012
Follow Pharmacy_Times:
In this podcast, a panel of experts discusses a range of topics relating to metastatic melanoma, including new treatment approaches, clinical trial updates, and managing side effects and pain. The participants on the panel were: Paul Chapman, MD, of the Memorial Sloan-Kettering Cancer Center; Gregory Daniels, MD, PhD, of the University of California San Diego; Mario Lacouture, MD, of the Memorial Sloan-Kettering Cancer Center; and Carolyn Messner, DSW, MSW, of CancerCare.
 
To listen to the podcast, click here.
Related Articles
Citing a risk of spreading unsuspected cancer, the FDA is advising against the use of laparoscopic power morcellators in the removal of the uterus or fibroids in the majority of women.
Amgen has discontinued its studies on rilotumumab in advanced gastric cancer after an increased number of deaths were reported among patients receiving rilotumumab and chemotherapy, compared with those only undergoing chemotherapy.
Clinical practice guidelines for the diagnosis and treatment of certain types of cancer are surprisingly unstandardized.
A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.
Latest Issues
$auto_registration$